Could This Tiny Device Help You Make an Extra $30k a Year?

I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.

Click here to see the details because I believe a lot of people will get rich.

Frederic Vanderhaegen net worth and biography

Frederic Vanderhaegen Biography and Net Worth

EVP of Avantor

Frederic Vanderhaegen is our Executive Vice President, Americas and Europe. He has a tenured background in strategic leadership in the life sciences, biopharmaceutical, medical device and research industries. Mr. Vanderhaegen leads our sales, marketing and customer service functions in both the Americas and Europe regions, as well as our global Sourcing and Laboratory Products Groups focused on solution-selling for critical workflows. Prior to joining Avantor, Mr. Vanderhaegen held leadership positions in organizations within the biopharma and life sciences industries, including Beckman Coulter, Tecan Group and MilliporeSigma. Most recently, he served as Vice President and General Manager, Europe, Middle East & Africa at Ortho-Clinical Diagnostics, leading sales and services. Mr. Vanderhaegen earned an MBA from The Open University Business School and also holds engineering degrees in biochemistry and chemical engineering.

What is Frederic Vanderhaegen's net worth?: The estimated net worth of Frederic Vanderhaegen is at least $3.41 million as of August 25th, 2023. Mr. Vanderhaegen owns 160,735 shares of Avantor stock worth more than $3,409,189 as of December 22nd. This net worth evaluation does not reflect any other assets that Mr. Vanderhaegen may own. Learn More about Frederic Vanderhaegen's net worth.
How do I contact Frederic Vanderhaegen?: The corporate mailing address for Mr. Vanderhaegen and other Avantor executives is BUILDING ONE SUITE 200 100 MATSONFORD ROAD, RADNOR PA, 19087. Avantor can also be reached via phone at (610) 386-1700 and via email at [email protected]. Learn More on Frederic Vanderhaegen's contact information.
Has Frederic Vanderhaegen been buying or selling shares of Avantor?: Frederic Vanderhaegen has not been actively trading shares of Avantor during the past quarter. Most recently, Frederic Vanderhaegen sold 25,000 shares of the business's stock in a transaction on Friday, August 25th. The shares were sold at an average price of $21.47, for a transaction totalling $536,750.00. Following the completion of the sale, the executive vice president now directly owns 160,735 shares of the company's stock, valued at $3,450,980.45. Learn More on Frederic Vanderhaegen's trading history.
Who are Avantor's active insiders?: Avantor's insider roster includes James Bramwell (EVP), Gerard Brophy (EVP), Christophe Couturier (EVP), Steven Eck (CAO), Rajiv Gupta (Director), Justin Miller (EVP), Jo Natauri (Director), Devashish Ohri (EVP), Christi Shaw (Director), Michael Stubblefield (President, CEO & Director), Thomas Szlosek (CFO), Frederic Vanderhaegen (EVP), and Michael Wondrasch (EVP). Learn More on Avantor's active insiders.
Are insiders buying or selling shares of Avantor?: In the last twelve months, insiders at the sold shares 2 times. They sold a total of 9,728 shares worth more than $240,247.97. The most recent insider tranaction occured on September, 5th when CAO Steven W Eck sold 3,525 shares worth more than $88,336.50. Insiders at Avantor own 1.5% of the company. Learn More about insider trades at Avantor.
Information on this page was last updated on 9/5/2024.

Frederic Vanderhaegen Insider Trading History at Avantor

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/25/2023	Sell	25,000	$21.47	$536,750.00	160,735
5/23/2022	Sell	39,000	$31.61	$1,232,790.00	126,764
11/12/2021	Sell	80,000	$38.25	$3,060,000.00
3/9/2021	Sell	10,000	$28.21	$282,100.00	243,669

Frederic Vanderhaegen Buying and Selling Activity at Avantor

Avantor Company Overview

Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, and compound management services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.

Today's Range

Now: $21.21

$20.95

$21.47

50 Day Range

MA: $22.15

$19.72

$25.06

2 Week Range

Now: $21.21

$19.59

$28.00

Volume

10,967,709 shs

Average Volume

6,461,251 shs

Market Capitalization

$14.44 billion

P/E Ratio

46.11

Dividend Yield

N/A

Beta

1.29